Captrust Financial Advisors Boosts Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Captrust Financial Advisors grew its stake in QuidelOrtho Co. (NASDAQ:QDEL) by 97.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,288 shares of the company’s stock after purchasing an additional 5,071 shares during the quarter. Captrust Financial Advisors’ holdings in QuidelOrtho were worth $458,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Quarry LP acquired a new stake in QuidelOrtho during the 4th quarter worth $43,000. Blue Trust Inc. raised its position in shares of QuidelOrtho by 188.0% in the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company’s stock valued at $58,000 after buying an additional 844 shares during the last quarter. Spire Wealth Management purchased a new position in shares of QuidelOrtho in the fourth quarter worth about $74,000. KBC Group NV boosted its position in QuidelOrtho by 122.9% during the fourth quarter. KBC Group NV now owns 3,437 shares of the company’s stock worth $153,000 after acquiring an additional 1,895 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its position in QuidelOrtho by 75.3% during the fourth quarter. Sterling Capital Management LLC now owns 3,726 shares of the company’s stock worth $166,000 after acquiring an additional 1,601 shares during the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Price Performance

QDEL stock opened at $32.57 on Tuesday. QuidelOrtho Co. has a 52-week low of $23.77 and a 52-week high of $49.45. The company has a quick ratio of 0.69, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -1.08 and a beta of 0.13. The business has a fifty day moving average of $30.85 and a two-hundred day moving average of $37.96.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.13. QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. The firm had revenue of $692.80 million for the quarter, compared to analyst estimates of $694.97 million. During the same period in the previous year, the firm earned $0.44 EPS. QuidelOrtho’s revenue was down 2.6% on a year-over-year basis. As a group, research analysts anticipate that QuidelOrtho Co. will post 2.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on QDEL shares. Royal Bank of Canada cut their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a report on Thursday, February 13th. UBS Group cut their price target on QuidelOrtho from $45.00 to $29.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. JPMorgan Chase & Co. lowered their price objective on QuidelOrtho from $38.00 to $25.00 and set an “underweight” rating on the stock in a research note on Monday, April 21st. Jefferies Financial Group upgraded QuidelOrtho from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a report on Thursday, May 8th. Finally, StockNews.com lowered QuidelOrtho from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $44.33.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.